share_log

Cantor Fitzgerald Initiates Coverage On KemPharm With Overweight Rating, Announces Price Target of $20

Benzinga Real-time News ·  Nov 17, 2022 19:25

Cantor Fitzgerald analyst Louis Chen initiates coverage on KemPharm (NASDAQ:KMPH) with a Overweight rating and announces Price Target of $20.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment